Hypothalamic AmenorrheaPhase 2NCT07224438
Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea
A Phase 2 study testing kisspeptin 112-121 in people with Hypothalamic Amenorrhea and Hypogonadotropic Hypogonadism, run by Stephanie B. Seminara, MD at 1 site in United States.
Trial summary
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Hypothalamic Amenorrhea, Hypogonadotropic Hypogonadism
- What is being tested?
- kisspeptin 112-121
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Dec 2025to May 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Female
- Ages 18-45 years
- Acquired HH (hypothalamic amenorrhea, aka functional hypogonadotropic hypogonadism)
- Normal blood pressure (systolic BP < 140 mm Hg, diastolic < 90 mm Hg)
- Hemoglobin no less than 0.5 g/dL below the lower limit of the reference range for normal women
- Negative serum hCG pregnancy test
- No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis OR willing to complete an appropriate washout for that particular medication and its method of administration
- If applicable, willing to use birth control methods (as approved by a study medical professional) during the entire study and for one month after the last dose of study drug
Who cannot join
- Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol
- Excessive alcohol consumption (>10 drinks/week)
- Active use of illicit drugs
- Pregnant
- Trying to become pregnant during protocol participation
- Breast feeding
- History of any of the following: bilateral oophorectomy (ovaries were removed), breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or undiagnosed abnormal genital bleeding
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Massachusetts General Hospital
Boston, Massachusetts, 02114
Study Coordinator, 617-643-2308, MGHKisspeptinResearch@partners.org
About this study
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.
Read the detailed description
Assignment: All study subjects will undergo the same interventions.
Delivery of Interventions:
- The subject will undergo a review of their medical history, physical exam, and screening laboratories.
- A pelvic ultrasound will be performed to assess baseline follicular size.
- A pump will be placed to administer pulsatile SC kisspeptin for two weeks.
- During the course of kisspeptin administration, subjects will
- Undergo q10 min blood sampling (approximately 4 sessions, 2 hours each)
- Undergo pelvic ultrasounds (approximately 4 sessions)
- Optional q10 min sampling up to 10 hours may take place before and after the course of kisspeptin
- Being tested
- kisspeptin 112-121
- Keywords
- hypothalamic amenorrhea, hypogonadotropic hypogonadism, kisspeptin
- Medical subject headings
- Hypogonadism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
kisspeptin 112-121Drug
Also called Metastin 45-54
SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)
| Study group | Role | What they receive |
|---|---|---|
| Kisspeptin pump | Experimental | SC administration of kisspeptin for two weeks (pulsatile) Receives: Drug: kisspeptin 112-121 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of luteinizing hormone (LH) pulse amplitude
Difference in LH amplitude on the first day of kisspeptin administration vs the last day of kisspeptin administration
Measured: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Nov 2025
- Study start9 Dec 2025
- Primary completionMay 2030 (estimated)
- Study completionMay 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypothalamic AmenorrheaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Stephanie B. Seminara, MD
- Sponsor type
- University, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Responsible party
- Sponsor-investigator, Stephanie B. Seminara, MD, Massachusetts General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07224438
- Sponsor's protocol ID
- 565178
- Other IDs
- R37HD043341
- Status last verified
- Jul 2026
- First submitted
- 3 Nov 2025
- Last updated
- 13 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea
- ClinicalTrials.gov ID
- NCT07224438
- Acronym / sponsor ID
- 565178
- Keywords
- hypothalamic amenorrhea, hypogonadotropic hypogonadism, kisspeptin
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Stephanie B. Seminara, MDUniversity, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Study start
- 9 Dec 2025 (actual)
- Primary completion
- May 2030 (estimated)
- Study completion
- May 2030 (estimated)
- First posted
- 4 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.
Detailed description
Assignment: All study subjects will undergo the same interventions.
Delivery of Interventions:
- The subject will undergo a review of their medical history, physical exam, and screening laboratories.
- A pelvic ultrasound will be performed to assess baseline follicular size.
- A pump will be placed to administer pulsatile SC kisspeptin for two weeks.
- During the course of kisspeptin administration, subjects will
- Undergo q10 min blood sampling (approximately 4 sessions, 2 hours each)
- Undergo pelvic ultrasounds (approximately 4 sessions)
- Optional q10 min sampling up to 10 hours may take place before and after the course of kisspeptin
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Kisspeptin pump | Experimental | Drug: kisspeptin 112-121SC administration of kisspeptin for two weeks (pulsatile) |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Female
- Ages 18-45 years
- Acquired HH (hypothalamic amenorrhea, aka functional hypogonadotropic hypogonadism)
- Normal blood pressure (systolic BP < 140 mm Hg, diastolic < 90 mm Hg)
- Hemoglobin no less than 0.5 g/dL below the lower limit of the reference range for normal women
Key exclusion criteria (7 listed)
- Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol
- Excessive alcohol consumption (>10 drinks/week)
- Active use of illicit drugs
- Pregnant
- Trying to become pregnant during protocol participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| kisspeptin 112-121Also: Metastin 45-54SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes) | Drug | Kisspeptin pump |
Primary outcome
Change of luteinizing hormone (LH) pulse amplitude
Time frame: 2 weeks
Difference in LH amplitude on the first day of kisspeptin administration vs the last day of kisspeptin administration
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Hypothalamic Amenorrhea
Recruiting
Feasibility of a Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA Pilot)
Functional Hypothalamic Amenorrhea
RecruitingPhase 2
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
Functional Hypothalamic Amenorrhea, FHA
RecruitingPhase 2
Role of Estrogen on Skeletal Outcomes in FHA
Bone Strength, Bone Density
Active, not recruitingObservational study
Hypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH)
Hypothalamic Amenorrhea
Not yet recruiting
Effects of Resistance Training on Women With Functional Hypothalamic Amenorrhea
Amenorrhea, Functional Hypothalamic Amenorrhea (FHA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing kisspeptin 112-121 in people with Hypothalamic Amenorrhea and Hypogonadotropic Hypogonadism, run by Stephanie B. Seminara, MD at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Study Coordinator (617-643-2308, MGHKisspeptinResearch@partners.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of luteinizing hormone (LH) pulse amplitude (time frame: 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026; AzTrials last refreshed its copy on 7 Nov 2026.